Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018183520) THERAPEUTIC AGENTS AND METHODS FOR ENHANCING IMMUNE RESPONSES IN TUMOR MICROENVIRONMENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/183520 International Application No.: PCT/US2018/024872
Publication Date: 04.10.2018 International Filing Date: 28.03.2018
IPC:
C07K 16/00 (2006.01) ,C07K 16/24 (2006.01) ,C07K 16/28 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
WANG, Jieyi [US/US]; US
LYVGEN BIOPHARMA HOLDINGS LIMITED; PO Box 31119 Grand Cayman, KY11-1205, KY
Inventors:
WANG, Jieyi; US
Agent:
CHEN, Yahua; US
Priority Data:
62/477,66128.03.2017US
Title (EN) THERAPEUTIC AGENTS AND METHODS FOR ENHANCING IMMUNE RESPONSES IN TUMOR MICROENVIRONMENT
(FR) AGENTS THÉRAPEUTIQUES ET MÉTHODES D'AMÉLIORATION DE RÉPONSES IMMUNITAIRES DANS UN MICRO-ENVIRONNEMENT TUMORAL
Abstract:
(EN) Human IgG1, IgG2, and IgG4 mutants having mutations in the hinge domain and exhibiting altered binding activity to Fcγ receptors such as FcγRIIB (CD32B). Also provided herein are methods for selectively activating immune responses in a subject using a therapeutic agent capable of targeting both an immune cell surface receptor and FcγRIIB.
(FR) La présente invention concerne des mutants IgG1, IgG2 et IgG4 humains ayant des mutations dans la région charnière et qui présentent une activité de liaison modifiée à des récepteurs Fcγ tels que FcγRIIB (CD32B). L'invention concerne également des procédés d'activation sélective de réponses immunitaires chez un sujet à l'aide d'un agent thérapeutique capable de cibler à la fois un récepteur de surface de cellule immunitaire et FcγRIIB
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)